Bristol Drug Patent Portfolio

Bristol owns 8 orange book drugs protected by 51 US patents with Krazati having the least patent protection, holding only 1 patent. And Pomalyst with maximum patent protection, holding 27 patents. Given below is the list of Bristol's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11680050 Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof 30 Sep, 2038
Active
US10689377 KRas G12C inhibitors 17 May, 2037
Active
US11452725 Chiral diaryl macrocycles and uses thereof 24 Jul, 2036
Active
US10294242 Diaryl macrocycle polymorph 05 Jul, 2036
Active
US9714258 Diaryl macrocycles as modulators of protein kinases 23 Jan, 2035
Active
US9181200 Pyrimidinedione compounds 19 Jun, 2034
Active
US9585883 Pyrimidinedione compounds 19 Jun, 2034
Active
USRE50050 Pyrimidinedione compounds 19 Jun, 2034
Active
US10000480 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses 07 Nov, 2033
Active
US11021475 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses 07 Nov, 2033
Active
USRE47929 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses 07 Nov, 2033
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
Active
US8828427 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 21 Dec, 2031
Active
US8828427 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 21 Jun, 2031
Active
US10555939 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 Nov, 2030
Active
US9993467 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 Nov, 2030
Active
US10239846 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis 15 Nov, 2030
Active
US8846628 Oral formulations of cytidine analogs and methods of use thereof 03 Jun, 2030
Active
US10555939 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 May, 2030
Active
US9993467 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 May, 2030
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
Active
US11571436 Oral formulations of cytidine analogs and methods of use thereof 14 May, 2029
Active
US12053482 Oral formulations of cytidine analogs and methods of use thereof 14 May, 2029
Active
US8481573 Modulators of sphingosine phosphate receptors 14 May, 2029
Active
US8796318 Modulators of sphingosine phosphate receptors 14 May, 2029
Active
US9382217 Modulators of sphingosine phosphate receptors 14 May, 2029
Active
US8198262 Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 17 Dec, 2025
Active
US8198262 Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 17 Jun, 2025
Active
US8673939 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 Nov, 2023 Expired
US8735428 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 Nov, 2023 Expired
US8673939 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 May, 2023 Expired
US8735428 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 May, 2023 Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020 Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Jun, 2019 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018 Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017 Expired
US6316471 Isoindolines, method of use, and pharmaceutical compositions 10 Aug, 2016 Expired
US8158653 Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline 10 Aug, 2016 Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 24 Jul, 2016 Expired
US5653517 Process and system for determination of friction/slip characteristics of road vehicle tires 24 Jul, 2016 Expired
US6476052 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Bristol.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 08 Jul, 2024 US8315886
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 24 Jun, 2024 US9585883
Email Notification 21 Mar, 2024 US10689377
Mail O.P. Petition Decision 21 Mar, 2024 US10689377
Mail-Record Petition Decision of Granted to Make Entity Status large 19 Mar, 2024 US10689377
Record Petition Decision of Granted to Make Entity Status large 18 Mar, 2024 US10689377
O.P. Petition Decision 16 Mar, 2024 US10689377
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9181200
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9585883
Initial letter Re: PTE Application to regulating agency 16 Feb, 2024 US9714258
Resp. to req. for info. sent under 37 CFR 1.750 15 Feb, 2024 US9714258
Maintenance Fee Reminder Mailed 05 Feb, 2024 US8204763
Change in Power of Attorney (May Include Associate POA) 22 Jan, 2024 US9714258
Email Notification 22 Jan, 2024 US9714258
Requirement for information sent under 37 CFR 1.750 16 Jan, 2024 US9714258


Bristol's Drug Patent Litigations

Bristol's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2015, against patent number US5635517. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8846628 February, 2023 Terminated-Settled
(05 Jan, 2024)
CELGENE CORPORATION et al. Apotex Inc. et al.
US6045501 April, 2015 Final Written Decision
(26 Oct, 2016)
Celgene Corporation Coalition For Affordable Drugs VI LLC
US6315720 April, 2015 FWD Entered
(26 Oct, 2016)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US5635517 May, 2015 Terminated-Denied
(16 Nov, 2015)
Celgene Corporation Coalition for Affordable Drugs VI LLC


Bristol Drug Patents' Oppositions Filed in EPO

Bristol drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 30, 2010, by Synthon B.V.. This opposition was filed on patent number EP03728969A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP20201105A Apr, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP20201105A Apr, 2023 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP20201105A Mar, 2023 Synthon BV Granted and Under Opposition
EP20201105A Mar, 2023 SANDOZ AG Granted and Under Opposition
EP20201105A Mar, 2023 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition
EP19213148A May, 2022 Generics [UK] Limited Granted and Under Opposition
EP19213148A May, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP19213148A May, 2022 TEVA PHARMACEUTICAL INDUSTRIES, LTD. Granted and Under Opposition
EP19213148A May, 2022 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Granted and Under Opposition
EP19213148A May, 2022 SANDOZ AG Granted and Under Opposition
EP19213148A Apr, 2022 Lotus Pharmaceutical Co., Ltd. Granted and Under Opposition
EP16180589A Oct, 2020 Cooke, Richard Granted and Under Opposition
EP16180589A Oct, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP13182721A Sep, 2020 SANDOZ AG Granted and Under Opposition
EP13182721A Sep, 2020 Hoffmann Eitle Granted and Under Opposition
EP13182721A Sep, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP13182721A Aug, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP16180589A Jan, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP18160247A Jan, 2020 Hoffmann Eitle Granted and Under Opposition
EP18160247A Jan, 2020 Generics (UK) Ltd Granted and Under Opposition
EP18160247A Jan, 2020 HGF Limited Granted and Under Opposition
EP18160247A Dec, 2019 Pruß, Timo Granted and Under Opposition
EP09746975A Aug, 2019 Generics (UK) Ltd Granted and Under Opposition
EP09746975A Aug, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP15199521A Aug, 2019 Bachelin, Martin, Dr. Revoked
EP15199521A Aug, 2019 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP15199521A Aug, 2019 Generics [UK] Ltd Revoked
EP15199526A Aug, 2019 Generics [UK] Ltd Revoked
EP15199540A Aug, 2019 Generics (UK) Ltd Revoked
EP15199521A Jul, 2019 Pruß, Timo Revoked
EP15199521A Jul, 2019 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP10830880A Dec, 2018 Generics [UK] Ltd Granted and Under Opposition
EP10720107A Oct, 2017 Hoffmann Eitle Revoked
EP10720107A Oct, 2017 STADA Arzneimittel AG Revoked
EP10720107A Oct, 2017 HGF Limited Revoked
EP10720107A Oct, 2017 Generics [UK] Ltd Revoked
EP10720107A Oct, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP12167590A May, 2017 Cooke, Richard Revoked
EP12167591A May, 2017 Cooke, Richard Revoked
EP12167591A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167590A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167589A May, 2017 Cooke, Richard Granted and Under Opposition
EP12167589A May, 2017 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP12167596A Apr, 2017 Cooke, Richard Revoked
EP12167596A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP09739981A Jun, 2016 Cooke, Richard Revoked
EP09739981A Jun, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP10703766A Apr, 2016 Cooke, Richard Revoked
EP10703766A Apr, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP07836007A Mar, 2016 Trösch, Dominique Granted and Under Opposition
EP07836007A Mar, 2016 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP07836007A Mar, 2016 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP09008756A Jul, 2015 Accord Healthcare Ltd Revoked
EP09008756A Jul, 2015 Generics [UK] Limited (trading as Mylan) Revoked
EP09008756A Jul, 2015 Hexal AG Revoked
EP09008756A Jul, 2015 Intellectual Property Services Revoked
EP09008756A Jul, 2015 Synthon B.V. Revoked
EP09008756A Jul, 2015 Actavis Group PTC EHF Revoked
EP04783095A Aug, 2012 Teva Pharmaceutical Industries Ltd. Revoked
EP04783095A Aug, 2012 Generics [UK] Limited Revoked
EP03728969A Dec, 2010 STRAWMAN LIMITED Revoked
EP03728969A Nov, 2010 Synthon B.V. Revoked


Bristol's Family Patents

Bristol drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 18.9% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Bristol Drug List

Given below is the complete list of Bristol's drugs and the patents protecting them.


1. Augtyro

Augtyro is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11452725 Chiral diaryl macrocycles and uses thereof 24 Jul, 2036
(11 years from now)
Active
US10294242 Diaryl macrocycle polymorph 05 Jul, 2036
(11 years from now)
Active
US9714258 Diaryl macrocycles as modulators of protein kinases 23 Jan, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Augtyro's drug page


2. Camzyos

Camzyos is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9181200 Pyrimidinedione compounds 19 Jun, 2034
(9 years from now)
Active
US9585883 Pyrimidinedione compounds 19 Jun, 2034
(9 years from now)
Active
USRE50050 Pyrimidinedione compounds 19 Jun, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Camzyos's drug page


3. Evotaz

Evotaz is protected by 6 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US6087383
(Pediatric)
Bisulfate salt of HIV protease inhibitor 21 Jun, 2019
(5 years ago)
Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018
(5 years ago)
Expired
US5849911
(Pediatric)
Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017
(6 years ago)
Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evotaz's drug page


4. Krazati

Krazati is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10689377 KRas G12C inhibitors 17 May, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Krazati's drug page


5. Onureg

Onureg is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8846628 Oral formulations of cytidine analogs and methods of use thereof 03 Jun, 2030
(5 years from now)
Active
US11571436 Oral formulations of cytidine analogs and methods of use thereof 14 May, 2029
(4 years from now)
Active
US12053482 Oral formulations of cytidine analogs and methods of use thereof 14 May, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onureg's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Pomalyst

Pomalyst is protected by 27 patents, out of which 19 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8828427
(Pediatric)
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 21 Dec, 2031
(7 years from now)
Active
US8828427 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 21 Jun, 2031
(6 years from now)
Active
US10555939
(Pediatric)
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 Nov, 2030
(5 years from now)
Active
US9993467
(Pediatric)
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 Nov, 2030
(5 years from now)
Active
US10555939 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 May, 2030
(5 years from now)
Active
US9993467 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione 19 May, 2030
(5 years from now)
Active
US8198262
(Pediatric)
Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 17 Dec, 2025
(1 year, 4 days from now)
Active
US8198262 Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 17 Jun, 2025
(6 months from now)
Active
US8673939
(Pediatric)
Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 Nov, 2023
(1 year, 28 days ago)
Expired
US8735428
(Pediatric)
Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 Nov, 2023
(1 year, 28 days ago)
Expired
US8673939 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 May, 2023
(1 year, 6 months ago)
Expired
US8735428 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione 15 May, 2023
(1 year, 6 months ago)
Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020
(4 years ago)
Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6316471 Isoindolines, method of use, and pharmaceutical compositions 10 Aug, 2016
(8 years ago)
Expired
US8158653 Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline 10 Aug, 2016
(8 years ago)
Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 24 Jul, 2016
(8 years ago)
Expired
US5653517 Process and system for determination of friction/slip characteristics of road vehicle tires 24 Jul, 2016
(8 years ago)
Expired
US6476052 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pomalyst's drug page


7. Sotyktu

Sotyktu is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10000480 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses 07 Nov, 2033
(8 years from now)
Active
US11021475 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses 07 Nov, 2033
(8 years from now)
Active
USRE47929 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses 07 Nov, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sotyktu's drug page


8. Zeposia

Zeposia is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11680050 Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof 30 Sep, 2038
(13 years from now)
Active
US10239846 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis 15 Nov, 2030
(5 years from now)
Active
US8481573 Modulators of sphingosine phosphate receptors 14 May, 2029
(4 years from now)
Active
US8796318 Modulators of sphingosine phosphate receptors 14 May, 2029
(4 years from now)
Active
US9382217 Modulators of sphingosine phosphate receptors 14 May, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zeposia's drug page


Bristol News

Bristol Myers secures approval for Opdivo combination as initial treatment for bladder cancer

07 Mar, 2024

GSK promotes new success with Blenrep combination following withdrawal, while analysts predict significant growth.

07 Mar, 2024

Multiple pharmaceutical companies including BeiGene, BMS, and AZ-FibroGen featured in Fierce Pharma Asia news.

01 Mar, 2024

Major American Pharmaceutical Companies Focus on Indian Market for Launching Their Popular Drugs, Including ...

28 Feb, 2024

See More